Copyright Reports & Markets. All rights reserved.

Global Pituitary ACTH Hypersecretion Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Pituitary ACTH Hypersecretion Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Pituitary ACTH Hypersecretion Drug Market Size Growth Rate by Product
      • 1.4.2 AT-814
      • 1.4.3 ATR-101
      • 1.4.4 BIM-23A758
      • 1.4.5 COR-005
      • 1.4.6 CORT-125134
      • 1.4.7 ISIS-GCCRRx
      • 1.4.8 Others
    • 1.5 Market by End User
      • 1.5.1 Global Pituitary ACTH Hypersecretion Drug Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Pituitary ACTH Hypersecretion Drug Market Size
      • 2.1.1 Global Pituitary ACTH Hypersecretion Drug Revenue 2014-2025
      • 2.1.2 Global Pituitary ACTH Hypersecretion Drug Sales 2014-2025
    • 2.2 Pituitary ACTH Hypersecretion Drug Growth Rate by Regions
      • 2.2.1 Global Pituitary ACTH Hypersecretion Drug Sales by Regions
      • 2.2.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Pituitary ACTH Hypersecretion Drug Sales by Manufacturers
      • 3.1.1 Pituitary ACTH Hypersecretion Drug Sales by Manufacturers
      • 3.1.2 Pituitary ACTH Hypersecretion Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Pituitary ACTH Hypersecretion Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Pituitary ACTH Hypersecretion Drug Revenue by Manufacturers
      • 3.2.1 Pituitary ACTH Hypersecretion Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Pituitary ACTH Hypersecretion Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Pituitary ACTH Hypersecretion Drug Price by Manufacturers
    • 3.4 Pituitary ACTH Hypersecretion Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Pituitary ACTH Hypersecretion Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Pituitary ACTH Hypersecretion Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Pituitary ACTH Hypersecretion Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Pituitary ACTH Hypersecretion Drug Sales by Product
    • 4.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Product
    • 4.3 Pituitary ACTH Hypersecretion Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Pituitary ACTH Hypersecretion Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Pituitary ACTH Hypersecretion Drug by Countries
      • 6.1.1 North America Pituitary ACTH Hypersecretion Drug Sales by Countries
      • 6.1.2 North America Pituitary ACTH Hypersecretion Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Pituitary ACTH Hypersecretion Drug by Product
    • 6.3 North America Pituitary ACTH Hypersecretion Drug by End User

    7 Europe

    • 7.1 Europe Pituitary ACTH Hypersecretion Drug by Countries
      • 7.1.1 Europe Pituitary ACTH Hypersecretion Drug Sales by Countries
      • 7.1.2 Europe Pituitary ACTH Hypersecretion Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Pituitary ACTH Hypersecretion Drug by Product
    • 7.3 Europe Pituitary ACTH Hypersecretion Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Pituitary ACTH Hypersecretion Drug by Countries
      • 8.1.1 Asia Pacific Pituitary ACTH Hypersecretion Drug Sales by Countries
      • 8.1.2 Asia Pacific Pituitary ACTH Hypersecretion Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Pituitary ACTH Hypersecretion Drug by Product
    • 8.3 Asia Pacific Pituitary ACTH Hypersecretion Drug by End User

    9 Central & South America

    • 9.1 Central & South America Pituitary ACTH Hypersecretion Drug by Countries
      • 9.1.1 Central & South America Pituitary ACTH Hypersecretion Drug Sales by Countries
      • 9.1.2 Central & South America Pituitary ACTH Hypersecretion Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Pituitary ACTH Hypersecretion Drug by Product
    • 9.3 Central & South America Pituitary ACTH Hypersecretion Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Pituitary ACTH Hypersecretion Drug by Countries
      • 10.1.1 Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales by Countries
      • 10.1.2 Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Pituitary ACTH Hypersecretion Drug by Product
    • 10.3 Middle East and Africa Pituitary ACTH Hypersecretion Drug by End User

    11 Company Profiles

    • 11.1 Alder Biopharmaceuticals Inc.
      • 11.1.1 Alder Biopharmaceuticals Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.1.5 Alder Biopharmaceuticals Inc. Recent Development
    • 11.2 Corcept Therapeutics Incorporated
      • 11.2.1 Corcept Therapeutics Incorporated Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.2.5 Corcept Therapeutics Incorporated Recent Development
    • 11.3 Cortendo AB
      • 11.3.1 Cortendo AB Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Cortendo AB Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Cortendo AB Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.3.5 Cortendo AB Recent Development
    • 11.4 Cyclacel Pharmaceuticals, Inc.
      • 11.4.1 Cyclacel Pharmaceuticals, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.4.5 Cyclacel Pharmaceuticals, Inc. Recent Development
    • 11.5 ElexoPharm GmbH
      • 11.5.1 ElexoPharm GmbH Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.5.5 ElexoPharm GmbH Recent Development
    • 11.6 Ipsen S.A.
      • 11.6.1 Ipsen S.A. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.6.5 Ipsen S.A. Recent Development
    • 11.7 Isis Pharmaceuticals, Inc.
      • 11.7.1 Isis Pharmaceuticals, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.7.5 Isis Pharmaceuticals, Inc. Recent Development
    • 11.8 Novartis AG
      • 11.8.1 Novartis AG Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Novartis AG Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Novartis AG Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.8.5 Novartis AG Recent Development
    • 11.9 Orphagen Pharmaceuticals, Inc.
      • 11.9.1 Orphagen Pharmaceuticals, Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.9.5 Orphagen Pharmaceuticals, Inc. Recent Development
    • 11.10 Pfizer Inc.
      • 11.10.1 Pfizer Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Products Offered
      • 11.10.5 Pfizer Inc. Recent Development

    12 Future Forecast

    • 12.1 Pituitary ACTH Hypersecretion Drug Market Forecast by Regions
      • 12.1.1 Global Pituitary ACTH Hypersecretion Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Pituitary ACTH Hypersecretion Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Pituitary ACTH Hypersecretion Drug Market Forecast by Product
      • 12.2.1 Global Pituitary ACTH Hypersecretion Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Pituitary ACTH Hypersecretion Drug Revenue Forecast by Product 2019-2025
    • 12.3 Pituitary ACTH Hypersecretion Drug Market Forecast by End User
    • 12.4 North America Pituitary ACTH Hypersecretion Drug Forecast
    • 12.5 Europe Pituitary ACTH Hypersecretion Drug Forecast
    • 12.6 Asia Pacific Pituitary ACTH Hypersecretion Drug Forecast
    • 12.7 Central & South America Pituitary ACTH Hypersecretion Drug Forecast
    • 12.8 Middle East and Africa Pituitary ACTH Hypersecretion Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Pituitary ACTH Hypersecretion Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Pituitary ACTH Hypersecretion Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pituitary ACTH Hypersecretion Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Pituitary ACTH Hypersecretion Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pituitary ACTH Hypersecretion Drug in these regions.
      This research report categorizes the global Pituitary ACTH Hypersecretion Drug market by top players/brands, region, type and end user. This report also studies the global Pituitary ACTH Hypersecretion Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Alder Biopharmaceuticals Inc.
      Corcept Therapeutics Incorporated
      Cortendo AB
      Cyclacel Pharmaceuticals, Inc.
      ElexoPharm GmbH
      Ipsen S.A.
      Isis Pharmaceuticals, Inc.
      Novartis AG
      Orphagen Pharmaceuticals, Inc.
      Pfizer Inc.

      Market size by Product
      AT-814
      ATR-101
      BIM-23A758
      COR-005
      CORT-125134
      ISIS-GCCRRx
      Others
      Market size by End User
      Clinic
      Hospital
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Pituitary ACTH Hypersecretion Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Pituitary ACTH Hypersecretion Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Pituitary ACTH Hypersecretion Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Pituitary ACTH Hypersecretion Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Pituitary ACTH Hypersecretion Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pituitary ACTH Hypersecretion Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now